Design: Retrospective chart reviews of 139 patients (87 males, median 3 The discovery of an endogenous cannabinoid system with specific receptors and ligands two decades ago has increased our understanding of the actions of exogenous cannabinoids found in cannabis on the human body. [4] [5] [6] The endocannabinoid system, which includes cannabinoid receptors, endogenous ligands, and other regulatory molecules, appears to be intricately involved in normal human physiology, specifically in the control of movement, pain, memory and appetite, mood, and inflammation, among other functions. 4, 5 An understanding of the biological basis of cannabinoid signaling gives the pain specialist a way to explain why the analgesic effects of cannabis and cannabinoids have been substantiated in a number of studies, including randomized, controlled trials.
INTRODUCTION
Recently, there has been widening interest in the viability of the medicinal use of cannabis or marijuana, with a call for further research from The National Institutes of Health (NIH), 1 a statement of support for consideration of the reclassification of cannabis' status as a Schedule I substance by the American College of Physicians (ACP), 2 and a recommendation for clinical use of medical cannabis (MC) for symptom relief in seriously ill patients in limited and locally implemented peer-reviewed treatment trials in a decade-old report by the Institute of Medicine (IOM). 3 The discovery of an endogenous cannabinoid system with specific receptors and ligands two decades ago has increased our understanding of the actions of exogenous cannabinoids found in cannabis on the human body. [4] [5] [6] The endocannabinoid system, which includes cannabinoid receptors, endogenous ligands, and other regulatory molecules, appears to be intricately involved in normal human physiology, specifically in the control of movement, pain, memory and appetite, mood, and inflammation, among other functions. 4, 5 An understanding of the biological basis of cannabinoid signaling gives the pain specialist a way to explain why the analgesic effects of cannabis and cannabinoids have been substantiated in a number of studies, including randomized, controlled trials. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Indeed, cannabinoids have been found to have analgesic effects "in virtually every experimental pain paradigm." 22 From a clinical drug therapy management standpoint, based on available extensive literature reviews, there is no risk of lethal overdose with MC use, the most frequently reported side effect in the published clinical trials data being mild euphoria. 23, 24 Additionally, MC dosing guidelines have also been put forward by clinicians, focusing on the principles of 'start low and go slow' and patient auto-titration. 25, 26 The recommendation that patients who wish to use MC be counseled to use oral ingestion or a vaporizer to avoid any health hazards of smoking has also been published. 27 There exists a population of chronic pain patients who are already on or have already tried opioids but wish to be treated with MC. This will become an increasingly important issue for pain management physicians to address because, as of the writing of this article, 13 states in the United States have functional MC programs, which legally protect physicians who wish to recommend MC from state or federal sanction, 27, 28 and several more states are seriously considering adoption of MC laws. Despite growing interest in cannabinoid medicine, little health and life quality documentation exists in the modern literature on US patients who receive authorizations to use MC from licensed physicians in accordance with state laws to treat chronic pain and illness. Four of the 13 active state MC programs-Oregon, Nevada, Colorado, and Rhode Island-have taken efforts to Web-publish health statistics collected from their state registries that describe their MC-using patient populations. In Washington State, where authorized MC-using patients number in the 20,000 range, 25 they have not been studied at all; in California, where an officially recognized MC patient population has existed for 13 years, a small handful of observational studies, all in the San Francisco Bay Area, have been published. [29] [30] [31] The studies can be divided into two groups: access-based and deliverybased. MC access-based studies are conducted at point of medical authorization and involve patient interviews, chart reviews, and treatment monitoring, and MC delivery-based studies are conducted at sites where patients are physically delivered treatment with MC and generally involve directed or randomized patient sampling and administration of survey instruments. As the focus of this article is on MC access-based studies in the United States, the peerreviewed literature in this area will be briefly reviewed. Currently, it consists of only three studies. First, Gieringer (2001) 29 reported data from a 2,480 patient panel treated by the late Tod Mikuriya, MD , a psychiatrist and widely published cannabinoid botanical medicine specialist. Mikuriya recorded more than 250 separate indications for MC under the International Classification of Disease Ninth Revision (ICD-9) system in these patients. One hundred percent of the patients had chronic conditions. On the basis of primary ICD-9 diagnosis, the largest category of patients interviewed by Mikuriya (1,133 patients, 45.7 percent) used MC for analgesia to treat conditions such as migraines and neuralgias, arthritis, musculoskeletal injuries, and degenerative disorders. The second largest category (660 patients, 26.6 percent) included patients who used MC to treat mood disorders, such as post-traumatic stress disorder, depression, bipolar disorder, and schizophrenia. The third largest category of patients (136 patients, 5.5 percent) used MC as a harm reduction substitute for problematic substance use, such as alcohol dependency (118 patients), opioid dependency (8 patients) , and other substance dependencies (10 patients). Second, Sylvestre et al. (2006) 30 reported in a prospective observational study that MC use improved retention and virological outcomes in patients who received standard interferon and ribavirin treatment for hepatitis C virus (HCV) at Organization to Achieve Solutions in Substance-Abuse (OASIS), a community-based nonprofit clinic providing medical and psychiatric treatment to recovering problematic substance users in Oakland, CA. The interferon/ribavirin treatment regimen is well-known for inducing painful and debilitating side effects, including fever, chills, muscle and joint aches, fatigue, headache, nausea, and depression. The study recruited 71 HCV+ recovering problematic substance users, of whom 22 (31 percent) used cannabis and 49 (69 percent) did not. The authors noted that the cannabis used by patients in the study "was often obtained with outside medical approval through local 'cannabis clubs' " (1, 058) . They showed that the cannabisusing group of treated patients were significantly more likely to remain on curative HCV treatment for at least 80 percent of the projected treatment duration (95 percent of cannabis users versus 67 percent of nonusers) and were three times more likely (54 percent of cannabis users versus 18 percent of nonusers) to be classified as sustained virological responders (no detectable virus 6 months after the end of treatment). Finally, O'Connell et al. (2007) 31 reported on the demographics, social characteristics, and patterns of cannabis and other drug use in 4,117 patients seeking access to MC at a thoracic surgeon's private practice in the San Francisco, California Bay Area during the period 2001-2007 based on data gathered from structured clinical interviews. Seventy-seven percent of the MC patients were male, 69 percent were Caucasian, and their median age was 32 years. Nearly all were already established cannabis users who self-medicated for a "mix of physical and emotional symptoms" (p. 5). Investigators found that, in this patient panel, once patients had established cannabis as their substance of choice, subsequent consumption of alcohol, and to a lesser degree, tobacco, diminished (p. 4). As a whole, these three MC access-based studies in California documented MC use in patients with chronic pain, patients undergoing poorly tolerated curative treatments, and patients with histories of problematic substance use.
To better understand the medical geography of MC access in Washington State, the present study was conducted to document MC utilization at a regional pain clinic. The present study is similar to the previous studies published on the Mikuryia, OASIS, and O'Connell patient panels in that it presents a comprehensive report and analysis of the total population of patients being managed with MC at a particular clinic. However, it differs from previous studies in that the patient panel presented here is unique population of patients-namely, those with chronic pain who present mainly via referral to a subspecialty pain management clinic who have been authorized to use cannabinoid botanicals as part of their pain management regimen. The purpose of this study was ultimately to gain a better understanding of the characteristics of this patient population, including factors such as gender, age, reasons for seeking treatment, diagnoses, levels of functionality, and how the use of MC impacted the use of other medications, including opioids.
STUDY DESIGN AND PROCEDURES
The study was sited at a regional pain clinic staffed by University of Washington (UW) faculty. One of the authors (GTC) provides access to MC treatment, information, and management to qualifying patients at this clinic. In conducting this study, the investigators acted as agents of the UW, and the chief administrator of the regional medical center with which the clinic is affiliated signed a letter of cooperation transferring study oversight responsibilities from the hospital institution to the UW IRB. Only 19 researchers in the United States have the necessary licenses to conduct research with cannabis supplied by federal agencies, 32 and of these, only two licensees have a currently active clinical research study. In this study, MC was not supplied to qualifying patients; patients only received medical authorization to engage in the use of MC use at the clinic, which they ultimately procured from various state-approved channels. The study was approved by the UW Human Subjects Division, Application No. 33067, with an approved Waiver of Health Insurance Portability and Accountability Act (HIPAA) Authorization, and a federal Certificate of Confidentiality (NCCAM 08-02) was issued by the NIH's National Center for Complementary and Alternative Medicine.
The study was conducted in 2007-2008 and based at a purposefully chosen office-based physical medicine and rehabilitation, neurology, and pain medicine outpatient clinical practice and referral site in southwest Washington State, where a proportion of patients are undergoing authorized MC treatment under the care of a state-licensed physician and UW faculty member. Retrospective chart reviews of the complete population of MC-using patients at this clinic were conducted, focusing on issues related to chronic pain management and functionality. All clinical data collected from charts were de-identified; patients' home zip codes were used to determine geographic areas from which patients traveled to access treatment (using the initial three digits of a zip code if the geographic unit formed by combining all zip Codes with the same three initial digits contains more than 20,000 people). A code number was assigned and tagged to each chart and any information that linked the code numbers with the identities of the patients was held in confidence by the medical practice.
The study began by separating out the charts of all patients at the clinic, ages 18 and older, who have access to MC treatment through valid documentation provided by treating physicians included in their medical records. These were the only inclusion criteria. Any patient who may have been also taking the cannabinoid receptor type 1 blocker drug rimonabant, first marketed by the pharmaceutical company Sanofi-Aventis and available from international sources, would be excluded. Medical records were scored for health indicators such as time since first MC authorization, qualifying condition(s), McGill Pain score records, functionality, chronic pain management, opioid and other pain medication usage and change over time, and screened for any issues related to MC cannabis access (previous barriers, referrals from physicians unwilling to provide documentation, etc). See Figure 1 for the official study chart review data collection form. All diagnostic data collected from charts was verified by one of the authors (GTC), who serves as the medical director of this clinic and is fellowship-trained in pain medicine. 
RESULTS

Diagnostic and treatment characteristics
One hundred thirty-nine patients' medical charts with valid documentation for their authorized MC use were identified, assigned a code number, 1 through 139, in random order, and reviewed. No patients were excluded due to concomitant use of a cannabinoid receptor-blocking drug. In many cases, medically relevant corroborating information supporting patients' diagnoses, such as such as mechanisms of injury, findings from imaging studies, surgical histories, and other etiological data, were collected in the chart review and summarized (see Appendix).
Demographic characteristics
The group consisted of 87 (63 percent) males with a median age of 47 years and 52 (37 percent) females with a median age of 48 years. Males ranged in age from 18 to 69 years old, and females ranged in age from 22 to 84 years old. Very little data on ethnicity were available.
Geographic characteristics
The MC-using patient population had home addresses that were predominantly (71.9 percent) in the same three-digit zip code area as the clinic site. Fewer and fewer patients from increasingly more distant three-digit zip code areas accessed MC treatment at the pain clinic. See Figure 2 for a map of patient home three-digit zip codes demonstrating distance-decay in estimated travel-to-clinic distances in this patient sample.
MC treatment duration characteristics
While all 139 patients had authorizations for the use of MC from this clinic, 15 patients (10.8 percent) had documentation of prior MC authorization from outside physicians also included in their medical records. In total, the sample contained 236.4 patient-years of authorized MC use, with one of the authors (GTC) serving as the primary authorizing physician for 225.4 (95.3 percent) of these patient-years. Patients ranged in authorization lengths from 11 days to 8.31 years. The median number of GTC-authorized patient-years in the sample was 1.12 years. Sixty percent of the GTC-authorized patient-years in the sample were in male patients, but female patients had on an average 0.18 years (~2 months) greater of authorized MC use than male patients.
Chronic pain characteristics
Using diagnostic and medical historical chart data, chronic pain documented in each MC-using patient was classified according to its syndromic nature and type . This classification scheme is based on chronic pain etiology and is drawn primarily from a recent classification scheme advanced by pain management researchers Ramamurthy et al. 33 Results are shown in the Appendix. Most patients (n ϭ 123, 88 percent) had more than one chronic pain syndrome or type present.
With regards to the distribution of chronic pain syndromes diagnosed in the patient population, myofascial pain syndromes were the most common (n ϭ 114, 82 percent), followed by neuropathic pain syndromes (n ϭ 89, 64 percent), discogenic back pain (n ϭ 72, 51.7 percent), and osteoarthritic pain (n ϭ 37, 26.6 percent). Central pain syndromes were present in 32 patients (23 percent), fibromyalgia pain in 19 patients (14 percent), visceral pain in 14 patients (10 percent), spinal cord injury pain in 8 patients (6 percent), rheumatoid arthritis pain in 6 patients (4 percent), diabetic neuropathic pain in 5 patients (4 percent), malignant pain in 5 patients (4 percent), phantom pain in 1 patient (1 percent), and HIV neuropathic pain in 1 patient (1 percent).
Characteristic access and delivery hurdles
Although patient records frequently documented significant symptom alleviation with MC and improved tolerance compared to other pain medications, the medical records of 37 percent of the patients in the sample (n ϭ 51) had documented instances of major hurdles related to accessing MC, such as: prior physicians unwilling to authorize use, legal problems related to MC use, and difficulties in finding an affordable and consistent supply of medicine. Although not all legal issues are detailed, the specific legal problems documented in the charts all stem from charges of possession, cultivation, or use of cannabis. In some cases, patients had prior MC authorizations which were not honored by authorities, and in other cases, patients had no MC authorizations in place prior to their legal problems but had previously been unable to find physicians willing to approve of this treatment modality.
DISCUSSION
The 139 patients accessing MC treatment for chronic pain at the study clinic in rural Washington State were a group of severely ill patients with extensive injurious and pathogenic exposures, including 14 with traumatic brain and closed head injuries, nine with HCV, four with past history of gunshot wounds (one in the head), three with past history of shrapnel wounds, five with spinal cord injuries, one with amyotrophic lateral sclerosis (ALS), one with primary lateral sclerosis (PLS), one with myotonia congenita, one with HIV, and 19 with fibromylagia syndrome.
There was a predominance of males (63 percent) in the clinic's patient population who were accessing treatment with MC, a trend seen in all prior published demographic data on the American MC-using patient population studied at access [29] [30] [31] and delivery sites. [34] [35] [36] [37] [38] [39] The reason for the predominance of males using MC is not clear, although there are many possibilities. Males are known to suffer more traumatic injuries resulting in chronic pain, which is reflective in our study population. Further, male patients may be willing to take greater risk with accessing a recently legalized treatment that still has considerable social stigma, with potential for criminal sanction, still attached. Other gender-specific factors could also be at play. Nonetheless, the male and female median ages did not significantly differ. Data also indicate that males and females are accessing MC at equal rates, given the similarity in median authorization times in males and females.
Geographically, most patients came from the 983 and 985 zip codes, which cover the following counties in Western Washington: Lewis, Thurston, Grays Harbor, Pacific, Mason, and Pierce. The spa-tial patterning in the geographic data highlights the regionality of MC access in the sample, whereby patients using MC originate predominantly from the areas surrounding the clinic rather than just from any part of the state, regardless of distance. Although the pain clinic is in a rural setting, it is a subspecialty referral site, and thus patients who are referred there for consultation and pain management often have not received satisfactory symptom control in primary care settings. A review of chart notes in their medical records shows that these patients on follow-up or in initial self-reports frequently received satisfactory treatment of their refractory pain conditions with MC. This is seen, for example, in the following chart notes from four patients (quotations taken verbatim from medical records found in the Appendix). Patient #101: "He has been using marijuana on his own, as he feels [it] gives him the best pain relief of anything that he has used." 2-3 inhalations on a MJ cigarette 2-3[x]/day, & this improves his pain levels drastically w/o incapacitating him.; Patient #7: "using MJ successfully on a daily basis; pain from 8-9/10->2-3/10; needs only ~2-3 inhalations from a MJ cigarette to get pain relief"; Patient #38: "marijuana daily with no SE; "only thing she is now currently using for pain"; Patient #67: "She has been using cannabis in the past and has had excellent results with respect to her migraine headaches. Using <1/4 oz/week". Moreover, there was no documentation in any of the medical records of patient cessation of MC use due to intolerance or any other medical reason.
A standard classification system for chronic pain diagnoses was used to describe the patient sample. Most patients (n ϭ 123, 88 percent) had more than one chronic pain syndrome or type present. Male patients had slightly more chronic pain syndromes (mean of 2.9) when compared with females (mean of 2.8), but it is not possible to determine if this difference is statistically significant as these are not randomly drawn samples of all MC-using chronic pain patients in Washington State. There does not appear to be any clear correlation between age and number of chronic pain diagnoses in this patient sample, as patients with 1, 2, 3, or 4 chronic pain syndromes are represented at all decades of life. However, it can be seen that no patient over the age of 65 had just one chronic pain syndrome present. The data indicate that myofascial pain syndromes were the most common in this study population, followed by neuropathic pain syndromes, discogenic back pain, and osteoarthritic pain. These syndromes often involve inflammatory pathophysiological mechanisms, and their treatment with cannabinoid botanicals is consistent with the known analgesic and anti-inflammatory pharmacological effects of cannabinoid medicines. 10, 40, 41 The data show that cannabinoid botanicals are being used to treat multiple pain syndromes in the same patient. Although patients presenting with chronic pain syndromes of multiple etiologies might raise the possibility that some of these polypain patients have somatoform disorders, the objective historical data found in their charts helps to substantiate the diagnoses of true chronic pain syndromes, rather than simply psychiatric illnesses manifesting as poly-pain. For example, if a patient has lumbar radiculopathy from discopathy in addition to multijoint degenerative osteoarthritis, this patient may well be suffering from three types of chronic pain syndromes: neuropathic, discogenic, and osteoarthritic. Even if there is a somatoform or psychiatric component to some patients' chronic pain, it is worth noting that MC can be used to treat some forms of psychiatric illness. 42 This includes the treatment of depression, which can have a significant mitigating effect on pain perception. 42 Cannabidiol (CBD), a biologically active component of cannabis present to varying degrees in cannabis strains, has been shown in signal transduction studies to act as an agonist with modest affinity at human 5-HT1a receptors. 43 Thus, CBD has useful potential in treating the depression that often accompanies chronic pain. 44 It is clear from the chart review data presented in the Appendix that many patients had also used or were currently using other non-cannabinoid analgesics in the course of their treatment at the pain clinic or at clinics they have previously visited. In the recorded clinical encounter chart notes, a frequently observed issue is that these previously or concomitantly used non-cannabinoid analgesic medications often had bothersome or intolerable side effects for these patients. The common opioid-related side effects such as constipation, nausea, reduced appetite, sedation, altered mental status, pruritis, and headaches are repeatedly documented. In the section of the Appendix where MC-specific chart notes are tabulated, 26 patients' charts (19 percent) record medical historical data indicating that MC was better than all other pain medications that they had used in the past and, in some cases, the only medication that they had found to be effective (see Because of the retrospective, nonquantitative methodology used, it is difficult to make any definitive statements regarding the relationship between opioid and MC use in this patient population. Moreover, chart data on comprehensive medication lists was at times unavailable, not up-to-date, or not detailed enough to discern patients' exact chronological sequence of starting and stopping all their medications. Nonetheless, some patients' charts records clearly note reductions in the dosages of concomitantly used opioids; ie, Patient #126: "states openly that he has used marijuana in the past and it has helped his pain substantially. Tolerates it much better than opiates and his use of marijuana has substantially decreased his dependence on opiates"; Patient #133: "he is using MC to control his pain with good luck with that. He also uses oxycodone and oxyContin, but he tries to limit this." On the basis of the underlying pharmacology, it is known that cannabinoids provide analgesia via specific, receptor-based mechanisms, independent of the mechanisms of opioids.
More than one-third of the patients in the study sample have had past or ongoing hurdles in accessing or being delivered cannabinoid botanicals for medical use. A MC authorization functions in many ways as an authorization for medical asylum from relevant substance control/drug enforcement policies. However, given the frequent presence of cannabis possession-related legal problems in this patient sample, medical amnesty from relevant state laws for the use of cannabinoid botanicals is imperfect and continues to be occasionally disruptable by law enforcement and other administrative actions, given that the exact letter of Washington State's MC law in its current form only provides an affirmative defense for qualifying patients. Additionally, due to the nonreimbursable cost and general unavailability of delivery systems, medical-grade cannabis is frequently difficult for patients with documented medical needs to obtain.
CONCLUSION: CLINICAL RELEVANCE
By providing a medical geographic patient utilization "snapshot" of 236.4 patient-years of the use of MC at a regional pain clinic, this study provides further insight into the applicability of cannabinoid botanicals in the management of a broad range of refractory chronic pain conditions in adults, from myofascial pain and discogenic back pain to neuropathic pain and central pain syndromes. With physicians employing proper chart documentation of appropriate use, efficacy, and side effects at patient visits, in a manner similar to that used in opioid management of pain, there will hopefully be additional reports in the future on MC use in pain management to add to the clinical database.
Such a literature can grow only if certain stereotypes and myths about MC use are dispelled amongst pain management specialists and their regulators. The results presented here should help to deconstruct mythologies about the kinds of patients accessing MC treatment, including their young age or their propensity to malinger or feign disease. One prominent mythology is that patients who receive treatment with MC are not "truly sick." 45 An examination of the chart review data, which includes both subjective and objective diagnostic data substantiating patients' chronic pain illnesses, helps to deflate this concern. Further, in this sample, there was a relatively even distribution among gender and age, without any significant predominance in younger, male patients. Additionally, by reviewing medical records kept at a pain clinic referral site directed by a physician in academic medicine, this article should help to dispel stereotypes and caricatures about valid and invalid treatment with botanical and non-botanical cannabinoid medicines, as the legal distinctions between the different types of cannabinoid medicines are sites of active cultural contestation. Efforts to influence public opinion about cannabinoid medicines are made by federal law enforcement spokespersons, as seen in the two illustrations in Figure 3 of "Dr. Pot" and "Dr. Pat" that appear on a Drug Enforcement Administration (DEA) prevention Web site targeted toward adolescent education entitled "Rx pot: a prescription for disaster." Some benefit w/ vicodin prn; no effect with muscle relaxers and other narcotics; very poor tolerance for opiates; hydrocodone does not work very well. "pain killers stopped working a long time ago."
